To map proteome changes between individuals with different mutation status and manifestation of disease, we analyzed 235 urine samples from two independent cross‐sectional cohorts each comprised of four subject groups: (i) healthy controls (HC, LRRK2−/PD−); (ii) non‐manifesting carriers (NMC) harboring the LRRK2 G2019S mutation (LRRK2+/PD−); (iii) idiopathic PD patients (iPD, LRRK2−/PD+); and (iv) manifesting PD patients with LRRK2 G2019S (LRRK2 PD, LRRK2+/PD+; Fig 1A and Table 1). Here, LRRK2 is linked to Parkinson disease.